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Purpose/Objective: Head and neck cancer patients were 
managed with surgery, radiotherapy and chemotherapy. 
Carotid artery damage and neurotoxicity were found in the 
past. This study aimed to estimate the risk of dementia in 
head and neck cancer population with long-term follow-up. 
Materials and Methods: The National Health Insurance (NHI) 
claims database and cancer registry databases in Taiwan 
from The Collaboration Center of Health Information 
Application (CCHIA) were linked for analysis. The head and 
neck cancer patients were included in the study from 
1/1/2002 to 12/31/2010. The follow up duration was since 
index day to 12/31/2012. The inclusion criteria were head 
and neck cancers, age > 20 years old, surgery, chemotherapy, 
concurrent chemotherapy, or surgery with adjuvant 
treatment done. The exclusion criteria were cancer 
diagnosed before head and neck cancer confirmed, died or 
dementia diagnosed within 2 years after treatment of head 
and neck cancers, stroke before index day, distant 
metastasis, carcinoma in situ, sarcoma, head and neck 
cancer recurrence, unknown gender and younger than 20 
years old. The total enrolled head and neck cancer patients 
were 20,135 persons. 
Results: In surgery alone, surgery and adjuvant 
chemoradiotherapy, and chemoradiotherapy without surgery 
groups, there were 1.44, 1.04, and 1.98 dementia incidence 
per 1,000 person-year, respectively. The crude hazard ratio 
(HR) of dementia were 1.84 (95% confidence interval, 1.21-
2.81) in radiation with/without chemotherapy (RT/CT) group. 
Adjusted for age groups, gender, clinical stage and the 
comorbidities, the HR were 1.68 (95% CI, 1.00-2.80). The 
dementia risk in head and neck cancer patients between 
different treatment modalities according Cox proportional 
hazard model revealed that the age > 65 years old and 
radiotherapy with/without chemotherapy (RT/CT) were risk 
factors (P < .001 and P = 0.049, respectively) (HR 16.46 and 
1.68, respectively). The risk of dementia in different clinical 
stage head and neck cancer patients were not statistically 
significant (95% CI, 1.13-7.19) in different treatment groups, 
whatever radiotherapy or not. But in young age (< 65 years 
old) head and neck patients received radiotherapy 
with/without chemotherapy (RT/CT), high risk of dementia 
was 2.96 folds (95% CI, 1.24-7.08) and adjusted HR was 3.54 
folds (95% CI, 1.32-9.51) to surgery alone group. Total 
radiation dose more than 6,660 cGy will result in 1.69 folds 
(95% CI, 0.97-2.95; P = 0.063) dementia risk trend than head 
and neck cancer patients with total radiation dose < 6,660 
cGy. 
Conclusions: High radiation dose (? 6,660cGy) will result in 
1.69 folds dementia risk trend in head and neck cancer 
patients and persistent escalated dementia incidence even 9 
years after radiotherapy. Young age (< 65 years old) head and 
neck cancer patients were susceptible for radiation therapy 
with high risk of dementia. We need to select patients better 
for dose de-escalation in young head and neck cancer 
patients and avoid unnecessary high dose to neck and areas 
near brain tissue, especially in Taiwan, the median age of 
head and neck patients was 53 years old. 
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Purpose/Objective: To evaluate the use of FDG-PET-CT as 
the principal investigation to assess tumour response and the 
need for further biopsies or surgery following radical 
chemoradiation for stage III/IV oropharyngeal SCC. 
Materials and Methods: A retrospective analysis was 
undertaken of the 130 patients who completed radical 
treatment for Stage III/IV SCC of the oropharynx at our 
centre over a 3-year period (2010-2013). All patients were 
treated with IMRT (65Gy/30 fractions) +/- platinum-based 
chemotherapy or cetuximab. Our practice is that patients 
routinely have a PET-CT approximately 3 months after 
treatment to assess response. 
Results: 119/130 (92%) patients had a PET-CT 3-4 months 
after treatment. The PET-CT findings and associated 
recommendations for further management are summarised in 
Table One. 83 (70%) had a complete response on either the 
initial PET-CT or on a follow-up scan 3-6 months later [Group 
1]. Equivocal or suspicious residual uptake was seen in 27 
(24%) patients [Group 2] - primary site only (10), neck only 
(12) and both primary & neck (5). In total, 15 of these 27 had 
negative biopsies/post-op histology (i.e. confirmed false 
positives). Salvage surgery to the primary site was performed 
in 2 patients (both with no residual malignancy on histology) 
and 11 patients had a salvage neck dissection (5 with 
confirmed residual malignancy on histology). In 9 (8%) 
patients, the PET-CT revealed new metastatic disease [Group 
3]. At a median follow-up of 28 months from treatment 
completion, the progression free survival rates (PFS) were: 
74% [all], 87% [Group 1], 56% [Group 2] and 0% [Group 3]. 
Having a reassuring initial PET-CT [Group 1] was associated 
with a significantly improved PFS (HR 0.12 [0.06-0.27], 
p<0.01).? 
 
 
Conclusions: A reassuring PET-CT following radical 
chemoradiation predicts for a high progression-free survival 
rate. Using the finding of equivocal/suspicious residual FDG 
uptake to select patients for repeat biopsies or salvage 
surgery appears successful but patients need to be counselled 
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of the significant possibility of negative histological findings 
following salvage surgery. 
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Purpose/Objective: To investigate the prognostic impact of 
adjuvant chemotherapy in patients with high-risk 
nasopharyngeal carcinoma (NPC).  
Materials and Methods: Our definition of high-risk NPC 
included patients with 1) neck node > 6 cm; 2) 
supraclavicular node metastasis; 3) skull base 
destruction/intracranial invasion plus multiple nodes 
metastasis; or 4) multiple neck nodes metastasis with one of 
nodal size > 4 cm. Four hundreds and three high-risk NPC 
patients completed full-course of concurrent 
chemoradiotherapy or neoadjuvant chemotherapy plus 
radiotherapy were retrospectively reviewed. Post-radiation 
adjuvant chemotherapy with oral tegafur-uracil (two capsules 
per day) for 12 months was administered to 154 patients, the 
remaining 249 patients did not receive any adjuvant 
chemotherapy. We analyzed the treatment outcome between 
patients with and without adjuvant chemotherapy. 
Results: Baseline patient characteristics at diagnosis (age, 
sex, pathological type, performance status, T-classification, 
N-classification) and previous treatment modality were 
comparable in both arms. After a median follow-up of 72 
months for surviving patients, 31.8% (49/154) and 42.2% 
(105/249) in patients with and without adjuvant 
chemotherapy developed tumor relapse respectively. The 5-
year distant metastasis and locoregional failure-free survival 
rates for patients with and without adjuvant chemotherapy 
were 82.1% vs. 68.5% (P=0.0018) and 84.3% vs. 82.6% 
(P=0.7848), respectively. Patients with adjuvant 
chemotherapy had better overall survival than those without 
adjuvant chemotherapy (5-year rates, 80.5% vs. 66.3%, 
P=0.0001). 
Conclusions: Adjuvant chemotherapy can reduce distant 
failure and improve overall survival in high-risk NPC patients 
after curative concurrent chemoradiotherapy or neoadjuvant 
chemotherapy + radiotherapy.  
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Purpose/Objective: In many of the previous studies of the 
clinical outcomes of radiotherapy (RT) alone, an interruption 
of RT was found to be a significant predictor of the local 
control. The efficacy of concurrent chemoradiotherapy 
(CCRT) using hyperfractionated RT was confirmed in a meta-
analysis. Hyperfractionated RT has resulted in increased 
severe acute complications. However, there have been no 
reports that have evaluated the prognostic impact of the 
overall treatment time or completion rate of concurrent 
chemotherapy in patients treated with CCRT using 
hyperfractionated RT. The purpose of this study was 
therefore to investigate the prognostic impact of the overall 
treatment time and completion rates of chemotherapy in 
patients with squamous cell carcinoma of the head and neck 
cancer (SCCHN) who were treated with CCRT using 
hyperfractionated RT. 
Materials and Methods: Sixty-nine consecutive patients with 
SCCHN were initially treated with definitive CCRT and were 
retrospectively analyzed. All 69 patients were treated with 
CCRT using hyperfractionated RT of 72 Gy in 60 fractions and 
daily carboplatin (25 mg/m2). The patients treated with 
other chemotherapeutic regimens or induction chemotherapy 
were excluded. Carboplatin was planned to be administered 
as an intravenous bolus immediately before the first daily 
fraction at a dose of 25 mg/m2 on every treatment day. On 
the intermission days of the hyperfractionated RT, 
carboplatin was not prescribed. After the intermission, CCRT 
using hyperfractionated RT plus daily carboplatin or 
hyperfractionated RT alone was resumed. Univariate analyses 
were performed using several factors including overall 
treatment days and days of RT without carboplatin to 
identify prognostic factors for the survival rates. 
Results: Median follow-up time was 46 months. The overall 
treatment days were as follows; 39-42 (n=16), 43-48 (n=29), 
49-54 (n=9) and ≥55 (n=15), and the days of RT without 
carboplatin; 0 (n=27), 1-5 (n=13), 6-10 (n=13) and ≥7 (n=16). 
The overall treatment time (≤48 days vs ≥49 days) was a 
significant prognostic factor for the local control, disease-
free survival and overall survival rates. The completion rate 
of chemotherapy, as the number of days of RT without 
carboplatin, was not a significant factor affecting any of the 
survival rates. The clinical stage was a significant factor 
associated with the LC, DFS DMFS and OS. The T stage was 
also a significant predictor of the LC, DFS and OS. 
Conclusions: This study demonstrated that the overall 
treatment time influenced the clinical outcomes in SCCHN 
patients treated with concurrent CCRT using 
hyperfractionated RT and daily carboplatin, while the impact 
of the completion rates of daily carboplatin was limited. 
Therefore, when acute toxicities caused a treatment 
interruption, hyperfractionated RT alone should be resumed 
as soon as possible. 
   
 
 
 
